CAR-T therapy
Highly skilled oncologists at leading global clinics widely use the innovative CAR-T therapy method for treating malignant neoplasms. This therapy is based on the use of specially engineered autologous cells derived from the patient.
CAR-T therapy is used for the most aggressive forms of cancer (particularly lymphomas), especially when other treatments have proven ineffective. According to research, the remission rate for patients whose bodies did not respond to other treatments has increased tenfold.
The one-year survival rate following the infusion of autologous T-cells ranges from 50% to 70%.
Procedure specifics in global clinics
CAR (Chimeric antigen receptor) therapy combines three groups of approaches in modern cancer treatment:
- Cell therapy: patients receive a biological preparation in the form of modified autologous cells.
- Immunotherapy: T-lymphocytes identify and destroy foreign cells in the body, such as myeloma or leukemia cancer cells.
- Gene therapy: after collection, T-lymphocytes undergo specialized preparation in a laboratory, where a chimeric antigen receptor is created on their surface to recognize and target tumors.
It usually takes around two weeks from the collection of the cells to their reinfusion into the body. The leukapheresis procedure (infusion of modified T-lymphocytes) itself lasts no more than four hours and is performed as a single session.
Numerous research centers and national cancer institutes continue to work on the development of an improved T-cell combination medicine that can fight all types of malignant tumors.
